FDA assembles adcomm to review GSK's Jemperli trial plans in rectal cancer

[cafead]

via The FDA’s Oncologic Drugs Advisory Committee will meet this Thursday to discuss whether proposed studies would support an accelerated approval for GSK’s Jemperli in rectal cancer — despite initial concerns about the trial plans.

article source